NASDAQ:MLNT - Melinta Therapeutics Stock Price, Price Target & More

$7.05 -0.05 (-0.70 %)

(As of 04/26/2018 04:00 PM ET)

Previous Close$7.05

Today's Range$6.95 - $7.30

52-Week Range$6.50 - $24.25

Volume92,742 shs

Average Volume161,386 shs

Market Capitalization$219.27 million

P/E Ratio-0.32

Dividend YieldN/A

Beta1.37

About Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:MLNT

CUSIP15130J10

Webwww.melinta.com

Phone312-767-0291

Debt

Debt-to-Equity Ratio0.55%

Current Ratio4.72%

Quick Ratio4.38%

Price-To-Earnings

Trailing P/E Ratio-0.32

Forward P/E Ratio-1.46

P/E GrowthN/A

Sales & Book Value

Annual Sales$33.86 million

Price / Sales6.52

Cash FlowN/A

Price / CashN/A

Book Value$2.31 per share

Price / Book3.05

Profitability

EPS (Most Recent Fiscal Year)($21.86)

Net Income$-58,910,000.00

Net Margins-550.46%

Return on Equity-45.75%

Return on Assets-32.78%

Miscellaneous

Employees300

Outstanding Shares31,330,000

How to Become a New Pot Stock Millionaire

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics (NASDAQ:MLNT) issued its quarterly earnings data on Tuesday, March, 13th. The biotechnology company reported ($1.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.89. The biotechnology company had revenue of $4.23 million for the quarter, compared to analyst estimates of $3.28 million. Melinta Therapeutics had a negative net margin of 550.46% and a negative return on equity of 45.75%. View Melinta Therapeutics' Earnings History.

What price target have analysts set for MLNT?

6 brokers have issued 12-month price objectives for Melinta Therapeutics' stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Melinta Therapeutics' stock price to reach $3.25 in the next year. View Analyst Ratings for Melinta Therapeutics.

Who are some of Melinta Therapeutics' key competitors?

Some companies that are related to Melinta Therapeutics include Access Pharmaceuticals (ABEO), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX), Mirati Therapeutics (MRTX), Vectura Group (VEGPF), Amarin (AMRN), ARMO BioSciences (ARMO), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), OptiNose (OPTN), Adamas Pharmaceuticals (ADMS), Deciphera Pharmaceuticals (DCPH), Vanda Pharmaceuticals (VNDA), Homology Medicines (FIXX) and GlycoMimetics (GLYC).

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:

Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
Mr. Daniel Mark Wechsler, Pres & CEO (Age 50)
Dr. Thomas A. Steitz Ph.D., Co-Founder
Dr. Peter B. Moore Ph.D., Co-Founder
Dr. William L. Jorgensen Ph.D., Co-Founder

Has Melinta Therapeutics been receiving favorable news coverage?

News coverage about MLNT stock has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Melinta Therapeutics earned a news impact score of 0.13 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.01 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Melinta Therapeutics?

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of MLNT stock can currently be purchased for approximately $7.05.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $219.27 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 312-767-0291 or via email at [email protected]

MarketBeat Community Rating for Melinta Therapeutics (MLNT)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		385 (Vote Outperform)
Underperform Votes:		261 (Vote Underperform)
Total Votes:		646

MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Melinta Therapeutics (NASDAQ:MLNT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Melinta Therapeutics in the last 12 months. Their average twelve-month price target is $3.25, suggesting that the stock has a possible downside of 53.90%. The high price target for MLNT is $4.00 and the low price target for MLNT is $2.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.17	2.17	2.17	1.94
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 11 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$3.25	$3.25	$3.25	$10.8962
Price Target Upside:	53.90% downside	79.37% downside	79.37% downside	354.01% upside

Melinta Therapeutics (NASDAQ:MLNT) Consensus Price Target History

Price Target History for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/30/2017	Gabelli	Upgrade	Sell -> Hold		High
11/30/2017	Ladenburg Thalmann	Upgrade	Neutral -> Buy		High
11/1/2017	Robert W. Baird	Upgrade	Underperform -> Neutral	$2.00	N/A
10/26/2017	Jefferies Group	Reiterated Rating	Hold -> Neutral		N/A
8/10/2017	Roth Capital	Downgrade	Buy -> Neutral	$8.00 -> $4.00	High
8/10/2017	Stifel Nicolaus	Reiterated Rating	Hold	$4.00	High
1/12/2017	JPMorgan Chase	Reiterated Rating	Hold		N/A
1/2/2017	Cowen	Reiterated Rating	Hold		N/A
1/2/2017	Cantor Fitzgerald	Set Price Target	Buy	$28.00	N/A
12/30/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A
12/30/2016	Morgan Stanley	Upgrade	Underweight -> Equal Weight	$5.00 -> $5.00	N/A
12/29/2016	WBB Securities	Downgrade	Buy -> Hold	$40.00 -> $4.00	N/A
12/29/2016	S&P Equity Research	Boost Price Target		$2.65 -> $3.15	N/A
12/20/2016	SunTrust Banks	Downgrade	Buy -> Sell	$18.00 -> $5.00	N/A
11/8/2016	Royal Bank of Canada	Reiterated Rating	Buy	$27.50	N/A
11/2/2016	UBS	Downgrade	Outperform -> Market Perform		N/A
11/2/2016	Raymond James	Reiterated Rating	Outperform -> Market Perform		N/A
5/10/2016	Janney Montgomery Scott	Reiterated Rating	Hold		N/A
5/2/2016	Leerink Swann	Reiterated Rating	Hold		N/A

(Data available from 4/26/2016 forward)

Melinta Therapeutics (NASDAQ:MLNT) Earnings History and Estimates Chart

Earnings by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.82 EPS
Next Year EPS Consensus Estimate: $-2.71 EPS

Melinta Therapeutics (NASDAQ MLNT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/13/2018	Q4 2017	($0.59)	($1.48)	$3.28 million	$4.23 million	View	Listen
11/2/2017	Q3 2017		($1.00)		$1.72 million	View	N/A
8/9/2017	Q2 2017	($0.32)	($0.23)	$3.58 million	$0.86 million	View	Listen
4/28/2017	Q1 2017	($0.53)	($0.37)	$3.55 million	$4.87 million	View	N/A
2/28/2017	Q4 2016	($0.57)	($0.60)	$4.19 million	$7.95 million	View	Listen
10/27/2016	Q3	($0.64)	($0.62)	$3.90 million	$4.00 million	View	Listen
8/1/2016	Q2	($0.67)	($0.51)	$3.89 million	$3.42 million	View	N/A
5/1/2016	Q1	($0.63)	($0.61)	$3.94 million	$2.70 million	View	N/A
2/24/2016	Q4	($0.59)	($0.48)	$3.89 million	$5.79 million	View	Listen
10/22/2015	Q315	($0.52)	($0.63)	$4.70 million	$2.50 million	View	Listen
7/29/2015	Q2	($0.41)	($0.57)	$4.60 million	$5.05 million	View	Listen
4/30/2015	Q1	($0.43)	($0.41)	$2.90 million	$13.96 million	View	Listen
2/25/2015	Q414	($0.46)	($0.46)	$3.50 million	$2.47 million	View	Listen
10/29/2014	Q314	($0.59)	($0.34)	$1.59 million	$7.77 million	View	N/A
7/29/2014	Q214	($0.56)	($0.49)	$2.56 million	$1.90 million	View	N/A
4/29/2014	Q114	($0.48)	($0.51)	$2.10 million	$3.10 million	View	N/A
2/27/2014	Q413	($0.42)	($0.51)	$1.25 million	$2.07 million	View	N/A
10/29/2013	Q313	($0.29)	($0.41)	$0.46 million	$1.20 million	View	N/A
7/30/2013	Q3 2013	($0.42)	($0.16)	$5.13 million	$4.60 million	View	N/A
4/25/2013	Q1 2013	($1.90)	($2.10)			View	N/A
2/28/2013	Q4 2012	($1.60)	($1.30)			View	N/A
11/8/2012	Q312		($0.24)			View	N/A
8/8/2012	Q2 2012	($1.05)	($2.25)			View	N/A
5/10/2012	Q1 2012	($2.15)	($1.31)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Melinta Therapeutics (NASDAQ:MLNT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Melinta Therapeutics (NASDAQ MLNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.50%
Institutional Ownership Percentage: 37.94%

Insider Trading History for Melinta Therapeutics (NASDAQ:MLNT)

Institutional Ownership by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ MLNT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/5/2018	Vatera Healthcare Partners Llc	Director	Buy	5,777,778	$13.50	$78,000,003.00
3/8/2017	Dov A Md Goldstein	Director	Sell	150,000	$3.55	$532,500.00	95
1/13/2017	Dov A Md Goldstein	Director	Sell	105,460	$3.40	$358,564.00	95
1/6/2017	Dov A Md Goldstein	Director	Sell	937,600	$3.41	$3,197,216.00	95
1/3/2017	David N Gill	Director	Buy	5,000	$2.94	$14,700.00	5,000
3/1/2016	David Moore	Insider	Buy	500	$16.18	$8,090.00	1,500
1/4/2016	Dov A. Md Goldstein	Director	Sell	842	$30.06	$25,310.52	50
12/15/2015	David W. Oldach	insider	Sell	10,000	$30.27	$302,700.00	1,100
11/9/2015	David W. Oldach	insider	Sell	12,200	$28.78	$351,116.00	1,100
10/26/2015	Garheng Kong	Director	Buy	2,830	$17.43	$49,326.90	2,830
6/22/2015	Dov A Md Goldstein	Director	Sell	50,000	$35.74	$1,787,000.00
5/23/2014	John Johnson	Director	Buy	10,000	$9.10	$91,000.00
6/19/2013	P Sherrill Neff	Director	Buy	265,000	$7.00	$1,855,000.00

(Data available from 1/1/2013 forward)

Melinta Therapeutics (NASDAQ MLNT) News Headlines

Source:

Date	Headline
	Melinta Therapeutics (MLNT) Announces Updates on Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens www.streetinsider.com - April 25 at 8:34 AM
	Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ... globenewswire.com - April 24 at 5:23 PM
	Melinta Therapeutics (MLNT) Announces Results from VABOMERE TANGO II Trial www.streetinsider.com - April 24 at 8:35 AM
	Melinta's Vabomere shows treatment effect in high-risk patients seekingalpha.com - April 23 at 5:02 PM
	Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in ... globenewswire.com - April 23 at 8:28 AM
	Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations finance.yahoo.com - April 23 at 8:28 AM
	$13.13 Million in Sales Expected for Melinta Therapeutics (MLNT) This Quarter www.americanbankingnews.com - April 21 at 2:54 AM
	Analysts Anticipate Melinta Therapeutics (MLNT) to Post -$1.27 EPS www.americanbankingnews.com - April 19 at 3:12 PM
	Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial ... globenewswire.com - April 17 at 8:54 AM
	Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018 finance.yahoo.com - April 16 at 8:31 AM
	Melinta Therapeutics (MLNT) Receives "Hold" Rating from Stifel Nicolaus www.americanbankingnews.com - April 11 at 3:24 PM
	Roth Capital Downgrades Melinta Therapeutics (MLNT) to Neutral www.americanbankingnews.com - April 10 at 10:31 PM
	Melinta Therapeutics (MLNT) Downgraded by Zacks Investment Research to Sell www.americanbankingnews.com - April 7 at 3:53 PM
	New Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/Vaborbactam www.prnewswire.com - April 5 at 5:05 PM
	Melinta Therapeutics, Inc. (MLNT) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 3:26 AM
	Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $13.13 Million www.americanbankingnews.com - April 4 at 2:46 AM
	Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather finance.yahoo.com - April 3 at 8:41 AM
	Melinta Therapeutics (MLNT) Upgraded to "Neutral" at Robert W. Baird www.americanbankingnews.com - April 2 at 3:15 PM
	Melinta Therapeutics (MLNT) Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 31 at 4:56 PM
	Equities Analysts Offer Predictions for Melinta Therapeutics, Inc.'s FY2022 Earnings (MLNT) www.americanbankingnews.com - March 30 at 7:40 AM
	Zacks Investment Research Upgrades Melinta Therapeutics (MLNT) to "Hold" www.americanbankingnews.com - March 17 at 2:08 PM
	Melinta Therapeutics' (MLNT) CEO Dan Wechsler on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 15 at 8:34 AM
	Melinta Therapeutics (MLNT) Announces Earnings Results www.americanbankingnews.com - March 14 at 9:50 AM
	Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release) globenewswire.com - March 14 at 9:00 AM
	Melinta Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference - GlobeNewswire (press release) globenewswire.com - March 14 at 9:00 AM
	Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference finance.yahoo.com - March 14 at 9:00 AM
	Melinta Therapeutics, Inc. to Host Earnings Call finance.yahoo.com - March 13 at 8:46 AM
	Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - March 13 at 8:46 AM
	Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe - GlobeNewswire (press release) globenewswire.com - March 8 at 8:43 AM
	Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe finance.yahoo.com - March 8 at 8:43 AM
	Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release) globenewswire.com - March 3 at 6:07 PM
	Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 2 at 8:35 AM
	Melinta Therapeutics, Inc. (MLNT) Expected to Post Quarterly Sales of $3.28 Million www.americanbankingnews.com - March 1 at 4:54 AM
	Melinta Therapeutics (MLNT) Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE in Patients with cUTI www.streetinsider.com - February 28 at 8:34 AM
	Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018 finance.yahoo.com - February 28 at 8:34 AM
	Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI finance.yahoo.com - February 27 at 5:42 PM
	Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Post Earnings of -$0.59 Per Share www.americanbankingnews.com - February 27 at 11:42 AM
	Melinta Therapeutics' Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for ... - GlobeNewswire (press release) globenewswire.com - February 20 at 8:29 AM
	Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina finance.yahoo.com - February 20 at 8:29 AM
	Melinta Therapeutics, Inc. (MLNT) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - February 13 at 1:38 AM
	$3.28 Million in Sales Expected for Melinta Therapeutics, Inc. (MLNT) This Quarter www.americanbankingnews.com - February 12 at 2:26 AM
	Melinta Therapeutics, Inc. (MLNT) Short Interest Up 68.2% in January www.americanbankingnews.com - February 11 at 1:32 AM
	Melinta Therapeutics (MLNT) Downgraded by Zacks Investment Research www.americanbankingnews.com - February 8 at 12:56 PM
	Melinta Therapeutics (MLNT) Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - February 3 at 7:40 PM
	Wired News – Melinta Launched Intravenous and Oral Formulations of Baxdela(TM) in the US finance.yahoo.com - January 31 at 10:09 AM
	Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States finance.yahoo.com - January 29 at 9:57 AM
	Analysts Expect Melinta Therapeutics, Inc. (MLNT) to Post -$0.59 Earnings Per Share www.americanbankingnews.com - January 24 at 9:24 PM
	Melinta Therapeutics, Inc. (MLNT) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - January 19 at 1:32 AM
	Vatera Healthcare Partners Llc Acquires 5,777,778 Shares of Melinta Therapeutics, Inc. (MLNT) Stock www.americanbankingnews.com - January 9 at 9:38 PM
	Zacks: Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $3.28 Million www.americanbankingnews.com - January 9 at 3:36 AM

Melinta Therapeutics (NASDAQ:MLNT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Melinta Therapeutics (NASDAQ:MLNT) Income Statement, Balance Sheet and Cash Flow Statement

Melinta Therapeutics (NASDAQ MLNT) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff